https://www.thebodypro.com/category/hiv-treatments-in-development/tag/conference-coverage

The Latest

Mexico City's Downtown At Twilight

IAS 2019: What to Expect in HIV Science

Next week, 6,000 HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.

The Genetic Mutation Behind the Only Apparent Cure for HIV Img

The Genetic Mutation Behind the Only Apparent Cure for HIV

The HIV-resistant gene mutation CCR5 delta 32 has an interesting past. Could it also be the future of HIV treatment and prevention?

Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies Img

Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies

Two oral presentations at CROI 2019 showed that dual therapy with long-acting monthly injections resulted in very low levels of virological failure with high participant preference for injections compared to oral combinations.

What You Need to Know About the Second Person Likely Cured of HIV Img

What You Need to Know About the Second Person Likely Cured of HIV

Richard Jefferys, an expert in HIV cure research, spoke to TheBodyPro about this new case of HIV remission -- and the danger in rushing to publish these stories, especially for people who live with stigma.

UK Patient Likely to Be the Second Person Cured of HIV: Two Further Cases at CROI 2019 of HIV Remission After Allogenic Stem Cell Transplants Img

UK Patient Likely to Be the Second Person Cured of HIV: Two Further Cases at CROI 2019 of HIV Remission After Allogenic Stem Cell Transplants

The procedure used in this case was similar to that used in the only previously confirmed HIV cure case, "Berlin patient" Timothy Ray Brown, albeit with a somewhat less aggressive approach.

Inching Towards an HIV Cure: bNAb and TLR-7 Agonist Reduce Viral Rebound Off-ART in Macaques Img

Inching Towards an HIV Cure: bNAb and TLR-7 Agonist Reduce Viral Rebound Off-ART in Macaques

Results from a proof-of-principle study in macaques showing that treatment with broadly neutralising antibodies might play a role in key stages for an HIV cure.

No HIV Evolution in Plasma or Lymph Nodes on Suppressive ART and No Impact From Further Intensification Img

No HIV Evolution in Plasma or Lymph Nodes on Suppressive ART and No Impact From Further Intensification

Two studies presented at CROI 2018 support the idea that ART reaches everywhere in the body that it needs to, and that residual ongoing HIV replication comes from HIV infected cells that were archived before ART was started.

Antibodies

Ibalizumab Effective Against Drug-Resistant HIV in 48-Week Data

The experimental drug ibalizumab, a monoclonal antibody, continues to effectively lower viral load in people with drug-resistant HIV through 48 weeks of treatment, as potential FDA approval nears.

D/C/F/TAF Noninferior to Continued Protease Inhibitor at Week 48 of Phase 3 Trial Img

D/C/F/TAF Noninferior to Continued Protease Inhibitor at Week 48 of Phase 3 Trial

A single-tablet combination D/C/F/TAF proved virologically noninferior to continuing a suppressive boosted protease inhibitor plus F/TDF at 48 weeks in the phase 3 randomized Emerald trial.

Dolutegravir/3TC Dual Therapy as Switch Option in Multiple Studies Img

Dolutegravir/3TC Dual Therapy as Switch Option in Multiple Studies

Two oral presentations and numerous posters at the 16th European AIDS Conference included new data on using dolutegravir-based dual ART (many with 3TC) as a switch option for people currently on stable three-drug ART.